Vanila M. Singh, MD, MACM Elected to Virpax Pharmaceuticals’ Board of Directors
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the election of Vanila M. Singh, MD, MACM, to its Board of Directors. Dr. Singh was the immediate past Chief Medical Officer in [...]
Virpax Pharmaceuticals Announces Appointment of Christopher M. Chipman, Chief Financial Officer
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial Officer. “As Chairman of the Audit Committee, it is with great pleasure that I welcome Chris [...]
Virpax Pharmaceuticals Strengthens Board of Directors with Appointment of Gary S. Jacob, Ph.D. to its Board
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Gary S. Jacob, Ph.D. to its Board of Directors.“We are pleased to welcome Dr. Jacob as a new independent director to [...]
Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on NES100 for the Management of Acute and Chronic Pain
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems today announced that it has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for NES100 which uses the Nanomerics [...]
Virpax Pharmaceuticals Selected for Two Presentations at the 2020 Special Operations Medical Association Exhibition
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2020 Special Operations Medical Association’s Training, Education, Scientific Assembly and Exhibition (SOMA) being held May 11-15, 2020, at the [...]
Virpax to Develop Its Molecular Envelope Technology (MET) Intranasal Enkephalin Formulation for the Management of PTSD
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd. Under the agreement, Virpax has exclusive global rights to use Nanomerics’ nanotechnology for the delivery of a metabolically labile intranasal [...]
Gerald Bruce Joins Virpax Pharmaceuticals as Executive Vice President, Commercial Operations
Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, today announced that Gerald W. Bruce, has joined Virpax as Executive Vice President, Commercial Operations. Mr. Bruce most recently served as Vice President of Sales for Specialized Nutrition at Danone North America. “We are pleased [...]
Virpax Pharmaceuticals Announces the Appointment of Three Independent Directors
Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, is pleased to announce the appointment of three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders held on Monday, September 9, 2019 [...]
Virpax Pharmaceuticals to Present at the 2019 Military Health System Research Symposium
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two posters at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and [...]
Virpax Pharmaceuticals Selected for Two Presentations at the 2019 Military Health System Research Symposium
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and [...]
Virpax Pharmaceuticals to Present at ThinkEquity Conference
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, today announced that Anthony P. Mack, Chairman and CEO of Virpax will be presenting at the ThinkEquity Conference at 12:30 p.m. ET on Thursday, May 2, 2019 in [...]
Virpax Pharmaceuticals Licenses Molecular Envelope Technology (MET) Intranasal Formulation From Nanomerics Ltd.
Virpax to Develop a Non-Opioid Molecular Envelope Technology (MET) Intranasal Formulation for the Management of Chronic Pain Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd. Under the agreement, [...]
Virpax Pharmaceuticals Announces Successful Pre-IND Meeting for LBL100
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals ("Virpax"), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, completed a successful pre-Investigational New Drug ("pre-IND") Meeting with [...]
[FEATURED] Is Biopharma Still Committed To Its Role In Public Health?
This article from Life Science Leader magazine features the views of top executives, including Virpax's CEO Anthony Mack, on how the life sciences industry business model meets public health obligations. Read more on lifescienceleader.com
Virpax Pharmaceuticals Reports Pre-IND Guidance From FDA for DSF100
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, received a written response from the US Food and [...]
[FEATURED] Virpax inks ‘patch-in-a-can’ deal for pain management
Virpax Pharmaceuticals has licensed MedPharm’s topical spray technology to develop a transdermal patch for non-opioid pain management products. Read more on in-pharmatechnologist.com
Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure
Virpax to Develop a Long-Acting Liposomal Gel (Lipogel) for Post-Operative Pain Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. [...]
Virpax Pharmaceuticals Licenses ‘Patch-in-a-Can’ MedSpray® Technology From MedPharm Ltd
Transdermal Delivery Technology Integrated Into DSF100 NSAID Spray Film 1.3% Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with MedPharm Ltd, a leading contract provider of topical and transdermal product design and [...]